Author

Sharan Srinivasan

Fred Hutch Cancer CenterORCID 0009-0000-4129-4568Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1

Frequent Co-Authors

Brock J. McKinneyiD· 2 shared James V. AlvareziD· 2 shared Anna-Lena B.G. VigiliD· 1 shared Ashley V. DiMarcoiD· 1 shared Ayaha ItokawaiD· 1 shared Douglas B. FoxiD· 1 shared Feinan WuiD· 1 shared Jessica N. BecerraiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Brock J. McKinneyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 17, 2025

Recurrent Breast Cancer Cells Depend on De novo Pyrimidine Biosynthesis to Suppress Ferroptosis

Kelley R. McCutcheon, Josh Wu, Yasemin Ceyhan Ozdemir…·James V. Alvarez

This study identifies de novo pyrimidine synthesis as a metabolic vulnerability in recurrent breast cancer cells that suppresses ferroptosis, with DHODH inhibition selectively targeting these cells.

DOI 10.1101/2025.11.17.688927

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer Research CommunicationsPeer-reviewedMay 1, 2025

APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer

Nina Marie G. Garcia, Jessica N. Becerra, Sharan Srinivasan…·James V. Alvarez

This study shows APOBEC3 activity supports drug-tolerant persister cells in EGFR inhibitor-resistant lung cancer by promoting transdifferentiation and mutation acquisition.

23 citationstop 1%

humanDNA methylation

𝕏 PostBluesky